• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Ankylosing spondylitis (AS) - Articles and news items

biosimilar-disease-drug

FDA approves Novartis’ biosimilar to treat multiple inflammatory diseases

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis…

ankylosing spondylitis featured

NICE recommends secukinumab for people with ankylosing spondylitis

Industry news / 4 August 2016 / National Institute for Health and Care Excellence (NICE)

The National Institute for Health and Care Excellence (NICE) has recommended innovative new drug secukinumab for treating ankylosing spondylitis, a type of arthritis that mainly affects the back….

sb5

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

Industry news / 18 July 2016 / Victoria White, Digital Content Producer

At an estimated $4billion a year, the reference product, Humira, is among the European Union’s largest single drug expenditures…

cosentyx

Novartis plans head-to-head studies of Cosentyx versus Humira

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis…

flixabi

Infliximab biosimilar Flixabi approved in the EU

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade…

Golimumab

Golimumab shows higher treatment persistence rates in patients with IMRD

Industry news / 16 February 2016 / Victoria White

A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.

cosentyx

FDA approves Novartis’ Cosentyx for AS and PsA

Industry news / 18 January 2016 / Victoria White

Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)…

cosentyx-2

CHMP recommends approval of Cosentyx for ankylosing spondylitis and psoriatic arthritis

Industry news / 23 October 2015 / Victoria White

Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis…

eular

Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR

Industry news / 11 June 2015 / Victoria White

Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR…

AbbVie Logo

AbbVie presents results from large global study of patient attitudes and adherence across six chronic inflammatory diseases

Industry news / 11 June 2014 / AbbVie

AbbVie announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +